Patient Power: Monoclonal Antibodies in Myeloma
Posted: Nov 22, 2017
Patient Power: Monoclonal Antibodies in Myeloma image

Monoclonal antibodies have now been in use in the myeloma clinic since November of 2015. Dr. Gareth Morgan of the University of Arkansas Medical Sciences (UAMS) Myeloma Institute shares how they work and where the field is headed. He mentions the development of bi-specific antibodies, which are new drugs that can link an immune cell with the target on the surface of myeloma cells for greater specificity and impact. Learn more about this new class of drugs in this recent show on Myeloma Crowd Radio.

What Do Monoclonal Antibodies Do in Myeloma? from Patient Power on Vimeo.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811